Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Introduction: Burning mouth syndrome (BMS) is a pathology with a low prevalence, affecting between 0.1% and 3.7% of the general population, the ratio between women and men is between 3 and 7:1. It is clinically characterized by a burning pain sensation, recurrent daily for more than 2 hours a day, persistent for more than 3 months and in a way that increases throughout the day and decreases at night, without presenting clinically evident causal lesions on the surface of the oral mucosa, nor changes in clinical sensory tests.
The description of the symptomatology varies according to the patient and may be related especially to psychogenic factors.
Patients report dry mouth/xerostomia and taste alterations, such as metallic or bitter taste. The most frequent location is on the tongue (tip and lateral borders), but it can also include the anterior palate, gingiva and lips.
Since the etiopathogenic factors that produce BMS are not clear, it is difficult to make advances in therapy. The available treatments aim to control the multiple factors related to BMS, thus reducing the symptoms described by patients. Among them, the literature describes low level laser photobiomodulation.
The success of the use of low level lasers for treatments in oral medicine is due to their biomodulatory activity and their ability to penetrate tissues. The analgesic action of laser radiation is due to the inhibition of nociceptive mediators and the release by the Central Nervous System (CNS) of endogenous analgesic substances such as endorphins, which hinders the transmission of the painful stimulus.
It has been verified that low power laser radiation therapy can be effective in reducing symptoms in patients with BMS. Importantly, low power laser therapy is non-invasive, well tolerated by patients.
Objectives: To confirm the hypothesis that the application of low power laser in the areas of oral burning can improve the symptomatology of BMS.
Material and methods: We propose a clinical study in 38 patients with idiopathic BMS, prospective, randomized, double-blind.
The study universe will be constituted by patients attended at the Oral Medicine, Oral Surgery and Implantology Unit of the Faculty of Dentistry of the University of Santiago de Compostela (USC).
The Hospital Anxiety and Depression Scale (HADS), quality of life (OHIP-14) and subjective sensation of dry mouth xerostomia inventory (XI) questionnaires will be applied to all the patients, and the amount of saliva will be quantitatively determined by means of the unstimulated global saliva test (TSG-I) using a millimetric absorbent paper strip, at the beginning, at the end of treatment and at the re-evaluation at two and six months.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Laser Group (GL) | Active Comparator | The patients will be submitted to eight sessions of low power laser. The radiation emission will be performed according to the protocol. |
|
| Control Group (CG) | Placebo Comparator | In these patients the investigators will use the same protocol applied in the experimental group (time and application values) but the laser device will be turn off. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Low frequency laser activated photobiomodulation | Radiation | Infravermelho: analgesia, tissue biostimulation. The number of laser application points will be determined based on the areas referred by the patients.
Time of 30 seconds in each application point, with dosage: 3 J/point. |
| Measure | Description | Time Frame |
|---|---|---|
| Pain reported | To evaluate the effect of 808 nm diode laser radiation (infrared) applied intraorally on areas where patients report burning mouth. The degree of pain/burning reported by patients using a visual analogue scale (VAS). Scale from 0 to 10, where zero means no pain and ten means severe pain. | 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Degree of anxiety of the patients | To evaluate the degree of anxiety of the patients, through the Hospital Anxiety and Depression Scale (HADS). For every question the patient must answer about the presence or frequency of the symptoms, with four possible answers. The score ranges from 0 to 3 points for every question, depending on the intensity of the symptoms. Therefore, the total HADS score ranges from 0 to 21 points for each subscale. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Removal criteria:
-Patients who for any reason fail to keep follow-up appointments.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Universidad de Santiago de Compostela | Santiago de Compostela | A Coruña | 15785 | Spain |
The investigators will anonymize and categorize the clinical data of the patients to share the information with the other researchers of the group.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D002054 | Burning Mouth Syndrome |
| D014987 | Xerostomia |
| D009912 | Oral Manifestations |
| ID | Term |
|---|---|
| D009059 | Mouth Diseases |
| D009057 | Stomatognathic Diseases |
| D012466 | Salivary Gland Diseases |
| D012816 | Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
One group will be lasered off and the other group will be lasered on.
|
| Low frequency laser photobiomodulation inactive | Other | The same protocol as the activated group |
|
| 6 months |
| Quality of life of the patients | Assess quality of life, using OHIP-14. For scoring the answers to each of the 14 questions in the OHIP-14, the following values are used: 0 = never, 1 = rarely, 2 = sometimes, 3 = frequently, 4 = always, with the maximum possible score reaching 56 points. | 6 months |
| Subjective sensation of dry mouth | Assess the subjective sensation of dry mouth through the xerostomia inventory. | 6 months |
| Quantitative measurement of saliva | Quantitative measurement of saliva through the unstimulated global saliva test (TSG-I). | 6 months |
| D013568 |
| Pathological Conditions, Signs and Symptoms |